BioVersys AG

As of June 30, 2026, BioVersys AG carries a market capitalization of 155.15M, placing it among publicly traded companies globally. Its enterprise value stands at 108.01M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BioVersys AG's next confirmed earnings release is scheduled for March 31, 2027.

As of June 30, 2026, BioVersys AG has 5.85M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, BioVersys AG maintains a current ratio of 7.86, meaning it holds 7.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, BioVersys AG's stock has declined approximately 0.43% over the past 52 weeks. The 50-day moving average sits at 26.27, while the 200-day moving average is 26.31.

As of June 30, 2026, BioVersys AG holds 69.31M in cash and equivalents against 22.18M in total debt, resulting in a net debt position of -47.53M. Total book value stands at 44.84M, with working capital of 66.30M providing operational flexibility.